Three phase 3 prostate cancer results from ESMO 2026 cover long-term survival with abiraterone in metastatic disease, Erleada before and after surgery, and an update on Truqap for PTEN-deficient ...

Rodger Allen has been training in sand dunes to prepare for his desert challenge.

Prostate cancer (PCa) represents a major health burden across Europe, and screening is already widely performed, predominantly through opportunistic PSA ...

Researchers at Endeavor Health and GoPath Diagnostics have developed a new genetic test that can help predict which men with prostate cancer are most likely to develop aggressive, life-threatening ...

Johnson & Johnson (J&J) said that an early-stage trial of JNJ-6143 (previously HLD-0915) found that the novel oral Regulated ...

An international phase 3 clinical trial that treated patients with high-risk localized and locally advanced prostate cancer ...

The Decipher genomic test could help doctors decide which high-risk prostate cancer patients need abiraterone hormone therapy ...

Updated ENZARAD findings show no significant metastasis-free survival benefit with enzalutamide, although patients receiving pelvic lymph node radiation may benefit from intensification.

U.S. pharmaceutical company Johnson & Johnson (J&J) is conducting clinical trials for the new prostate cancer (prostate gland ...

C, explains why a prostate cancer diagnosis should be seen as a change in direction, not an ending, and how patients can lean ...

Recent study links blood proteins to aggressive prostate cancer, identifying potential biomarkers for early risk prediction ...

Women can get cancer in the Skene’s glands, sometimes called the “female prostate.” Skene’s gland cancer is very rare, with only about 20 reported cases to date. Treatment for Skene’s gland cancer may ...